Publications

Found 35 results
Filters: Author is Boggon, Titus J  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Fisher, O. S., Zhang, R., Li, X., Murphy, J. W., Demeler, B., and Boggon, T. J. (2013) Structural studies of cerebral cavernous malformations 2 (CCM2) reveal a folded helical domain at its C-terminus. FEBS Lett. 587, 272-7
Fisher, O. S., Deng, H., Liu, D., Zhang, Y., Wei, R., Deng, Y., Zhang, F., Louvi, A., Turk, B. E., Boggon, T. J., and Su, B. (2015) Structure and vascular function of MEKK3-cerebral cavernous malformations 2 complex. Nat Commun. 6, 7937
Ha, B. Hak, Simpson, M. Adam, Koleske, A. J., and Boggon, T. J. (2015) Structure of the ABL2/ARG kinase in complex with dasatinib. Acta Crystallogr F Struct Biol Commun. 71, 443-8
Alicea-Velázquez, N. L., Jakoncic, J., and Boggon, T. J. (2013) Structure-guided studies of the SHP-1/JAK1 interaction provide new insights into phosphatase catalytic domain substrate recognition. J Struct Biol. 181, 243-51
Yun, C. -hong, Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., and Eck, M. J. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 11, 217-27
Gao, J., Ha, B. Hak, Lou, H. Jane, Morse, E. M., Zhang, R., Calderwood, D. A., Turk, B. E., and Boggon, T. J. (2013) Substrate and inhibitor specificity of the type II p21-activated kinase, PAK6. PLoS One. 8, e77818
T
Stiegler, A. L., Vish, K. J., and Boggon, T. J. (2022) Tandem engagement of phosphotyrosines by the dual SH2 domains of p120RasGAP. Structure. 30, 1603-1614.e5
Simon, B., Lou, H. Jane, Huet-Calderwood, C., Shi, G., Boggon, T. J., Turk, B. E., and Calderwood, D. A. (2022) Tousled-like kinase 2 targets ASF1 histone chaperones through client mimicry. Nat Commun. 13, 749
Ha, B. Hak, Davis, M. J., Chen, C., Lou, H. Jane, Gao, J., Zhang, R., Krauthammer, M., Halaban, R., Schlessinger, J., Turk, B. E., and Boggon, T. J. (2012) Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate. Proc Natl Acad Sci U S A. 109, 16107-12
Hitosugi, T., Zhou, L., Fan, J., Elf, S., Zhang, L., Xie, J., Wang, Y., Gu, T. - L., Alečković, M., LeRoy, G., Kang, Y., Kang, H. - B., Seo, J. - H., Shan, C., Jin, P., Gong, W., Lonial, S., Arellano, M. L., Khoury, H. J., Chen, G. Z., Shin, D. M., Khuri, F. R., Boggon, T. J., Kang, S., He, C., and Chen, J. (2013) Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nat Commun. 4, 1790

Pages